Jasper Therapeutics, Inc. financial data

Symbol
JSPR, JSPRW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2200 Bridge Pkwy Suite #102, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Amplitude Healthcare Acquisition Corp (to 9/29/2021)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 942 % -15.2%
Debt-to-equity 15.6 % +1.43%
Return On Equity -35.3 % -111%
Return On Assets -30.6 % -111%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares
Common Stock, Shares, Outstanding 15M shares -86.5%
Entity Public Float 111M USD +127%
Common Stock, Value, Issued 2K USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 15M shares +46.6%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +46.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 49.9M USD +5.62%
General and Administrative Expense 18.8M USD +6.48%
Operating Income (Loss) -68.7M USD -5.85%
Nonoperating Income (Expense) 1.25M USD -31.1%
Net Income (Loss) Attributable to Parent -33.2M USD +61.1%
Earnings Per Share, Basic -1.65 USD/shares +73.5%
Earnings Per Share, Diluted -1.65 USD/shares +73.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 92.5M USD -10.9%
Marketable Securities, Current 3.4M USD
Other Assets, Current 625K USD
Assets, Current 94.8M USD -9.9%
Property, Plant and Equipment, Net 2.07M USD -25.5%
Operating Lease, Right-of-Use Asset 1.11M USD -30%
Other Assets, Noncurrent 1.01M USD +146%
Assets 99.4M USD -9.96%
Accounts Payable, Current 3.09M USD -5.22%
Employee-related Liabilities, Current 2.57M USD +83.4%
Liabilities, Current 12.5M USD +4.65%
Operating Lease, Liability, Noncurrent 1.01M USD -51.2%
Other Liabilities, Noncurrent 2.26M USD -1.44%
Liabilities 15.7M USD -3.31%
Retained Earnings (Accumulated Deficit) -217M USD -41.5%
Stockholders' Equity Attributable to Parent 83.7M USD -11.1%
Liabilities and Equity 99.4M USD -9.96%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.7M USD -52.3%
Net Cash Provided by (Used in) Financing Activities 47.3M USD -53.4%
Net Cash Provided by (Used in) Investing Activities -25K USD +3.85%
Common Stock, Shares Authorized 492M shares 0%
Common Stock, Shares, Issued 15M shares -86.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 92.9M USD -10.9%
Deferred Tax Assets, Valuation Allowance 16.2M USD +60.4%
Deferred Tax Assets, Gross 47M USD +36.1%
Operating Lease, Liability 2.07M USD -31.4%
Lessee, Operating Lease, Liability, to be Paid 2.22M USD -34%
Property, Plant and Equipment, Gross 5.66M USD +14.2%
Operating Lease, Liability, Current 1.06M USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 740K USD -37.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.19M USD +2.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 151K USD -57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 740K USD -37.7%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +21.7%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.42M USD +40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 740K USD
Operating Lease, Payments 285K USD +3.26%
Additional Paid in Capital 300M USD +21.5%
Depreciation, Depletion and Amortization 300K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 488K USD -13.3%
Share-based Payment Arrangement, Expense 2M USD +43.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%